-
1Academic Journal
Authors: Avdeeva V.E., Kotov A.S.
Source: Russian Journal of Child Neurology; Vol 18, No 1 (2023); 10-21 ; Русский журнал детской неврологии; Vol 18, No 1 (2023); 10-21 ; 2412-9178 ; 2073-8803
Subject Terms: acute disseminated encephalomyelitis, myelin oligodendrocyte glycoprotein, multiple sclerosis, AQP-4, острый рассеянный энцефаломиелит, миелин-олигодендроцитарный гликопротеин, рассеянный склероз
File Description: application/pdf
Relation: https://rjdn.abvpress.ru/jour/article/view/430/292; https://rjdn.abvpress.ru/jour/article/view/430
-
2Academic Journal
Authors: V. E. Avdeeva, A. S. Kotov, В. Е. Авдеева, А. С. Котов
Source: Russian Journal of Child Neurology; Том 18, № 1 (2023); 10-21 ; Русский журнал детской неврологии; Том 18, № 1 (2023); 10-21 ; 2412-9178 ; 2073-8803 ; undefined
Subject Terms: AQP-4, myelin oligodendrocyte glycoprotein, multiple sclerosis, миелин-олигодендроцитарный гликопротеин, рассеянный склероз
File Description: application/pdf
Relation: https://rjdn.abvpress.ru/jour/article/view/430/292; Almaghrabi N., Saab A. Adult onset acute disseminated encephalomyelitis: A case report. Radiol Case Rep 2021;16(9):2469–73. DOI:10.1016/j.radcr.2021.05.052; Anilkumar A.C., Foris L.A., Tadi P. Acute Disseminated Encephalomyelitis. In: StatPearls. Treasure Island: StatPearls Publishing, 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK430934/; Ayed H., Chaudhary M.W., AlBaradie R., Mir A. Use of cyclophosphamide in a child with fulminant acute disseminated encephalomyelitis. Child Neurol Open 2018;5:2329048X18754631. DOI:10.1177/2329048X18754631; Boesen M.S., Langkilde A.R., Ilginiene J. et al. Oligoclonal bands, age 11-17 years, occipital lesion, and female sex differentiate pediatric multiple sclerosis from acute disseminated encephalomyelitis: A nationwide cohort study. Mult Scler Relat Disord 2022;66:104008. DOI:10.1016/j.msard.2022.104008; Hyun J.W., Huh S.Y., Shin H.J. et al. Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis. Mult Scler 2019;25(4):585–90. DOI:10.1177/1352458518761186; Iype M., Kunju M., Saradakutty G. et al. Short term outcome of ADEM: Results from a retrospective cohort study from South India. Mult Scler Relat Disord 2017;18:128–34. DOI:10.1016/j.msard.2017.09.018; Jarius S., Paul F., Aktas O. et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018;15(1):134. DOI:10.1186/s12974-018-1144-2; Kawanaka Y., Ando K., Ishikura R. et al. Delayed appearance of transient hyperintensity foci on T1-weighted magnetic resonance imaging in acute disseminated encephalomyelitis. Jpn J Radiol 2019;37(4):277–82. DOI:10.1007/s11604-018-00808-w; Ketelslegers I.A., Visser I.E., Neuteboom R.F. et al. Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children. Mult Scler 2011;17(4):441–8. DOI:10.1177/1352458510390068; Kunchok A., Zekeridou A., McKeon A. Autoimmune glial fibrillary acidic protein astrocytopathy. Curr Opin Neurol 2019;32(3):452–8. DOI:10.1097/WCO.0000000000000676; López-Chiriboga A.S., Majed M., Fryer J. et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgGassociated disorders. JAMA Neurol 2018;75(11):1355–63. DOI:10.1001/jamaneurol.2018.1814; Mahapure K.S., Prabhune A.S., Chouvhan A.V. COVID-19-associated acute disseminated encephalomyelitis: A systematic review. Asian J Neurosurg 2021;16(3):457–69. DOI:10.4103/ajns.AJNS_406_20; Makuuchi Y., Nishimoto M., Yamamoto K. et al. Successful treatment with rituximab in acute disseminated encephalomyelitis with whole spinal cord involvement following HLA haploidentical transplantation. Rinsho Ketsueki 2018;59(12):2588–93. DOI:10.11406/rinketsu.59.2588; Manzano G.S., McEntire C.R.S., Martinez-Lage M. et al. Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19: Systematic review and meta-synthesis. Neurol Neuroimmunol Neuroinflamm 2021;8(6):e1080. DOI:10.1212/NXI.0000000000001080; Massa S., Fracchiolla A., Neglia C. et al. Update on acute disseminated encephalomyelitis in children and adolescents. Children (Basel) 2021;8(4):280. DOI:10.3390/children8040280; Mikaeloff Y., Caridade G., Husson B. et al. Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. Eur J Paediatr Neurol 2007;11(2):90–5. DOI:10.1016/j.ejpn.2006.11.007; Narayan R., Simpson A., Fritsche K. et al. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2018;25:66–72. DOI:10.1016/j.msard.2018.07.025; Narayan R.N., Wang C., Greenberg B.M. Acute disseminated encephalomyelitis (ADEM) and increased intracranial pressure associated with anti-myelin oligodendrocyte glycoprotein antibodies. Pediatr Neurol 2019;99:64–8. DOI:10.1016/j.pediatrneurol.2019.03.009; Paolilo R.B., Deiva K., Neuteboom R. et al. Acute disseminated encephalomyelitis: Current perspectives. Children (Basel) 2020;7(11):210DOI: 10.3390/children7110210; Pohl D., Alper G., Van Haren K. et al. Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome. Neurology 2016;87(9 Suppl 2):S38–S45. DOI:10.1212/WNL.0000000000002825; Pruss H. Autoantibodies in neurological disease. Nat Rev Immunol 2021;21(12):798–813. DOI:10.1038/s41577-021-00543-w; Thompson A.J., Banwell B.L., Barkhof F. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17(2):162–73. DOI:10.1016/S1474-4422(17)30470-2; Vogrig A., Janes F., Gigli G.L. et al. Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. Clin Neurol Neurosurg 2021;208:106839. DOI:10.1016/j.clineuro.2021.106839; Wang C.X. Assessment and management of acute disseminated encephalomyelitis (ADEM) in the pediatric patient. Paediatr Drugs 2021;23(3):213–21. DOI:10.1007/s40272-021-00441-7; Wingerchuk D.M., Banwell B., Bennett J.L. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177–89. DOI:10.1212/WNL.0000000000001729; Yamamoto D., Uchiyama T., Ohashi T., Iizuka T. Case of steroidresponsive unilateral encephalitis with anti-myelin oligodendrocyte glycoprotein antibodies. Neurol Clin Neurosci 2017;5(3):101, 102. DOI:10.1111/ncn3.12119; Yanagida A., Iizuka T., Nagai T. et al. MOG-IgG-positive multifocal myelitis with intrathecal IgG synthesis as a spectrum associated with MOG autoimmunity: two case reports. J Neurol Sci 2017;382:40–3. DOI:10.1016/j.jns.2017.09.020; Zghali M.G. Tumefactive acute disseminated encephalomyelitis. Neurol India 2020;68(1):35–41. DOI:10.4103/0028-3886.279688; https://rjdn.abvpress.ru/jour/article/view/430
-
3Academic Journal
Authors: V. E. Avdeeva, A. S. Kotov, В. Е. Авдеева, А. С. Котов
Source: Russian Journal of Child Neurology; Том 16, № 3 (2021); 21-33 ; Русский журнал детской неврологии; Том 16, № 3 (2021); 21-33 ; 2412-9178 ; 2073-8803 ; 10.17650/2073-8803-2021-16-3
Subject Terms: острый рассеянный энцефаломиелит, myelin-oligodendrocytic glycoprotein, AQP-4, aquaporin 4, neuromyelitis optic spectrum diseases, optic neuritis, myelitis, acute disseminated encephalomyelitis, миелин-олигодендроцитарный гликопротеин, аквапорин 4, заболевания спектра оптиконевромиелита, оптический неврит, миелит
File Description: application/pdf
Relation: https://rjdn.abvpress.ru/jour/article/view/371/251; De Seze J. MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease? Brain 2017;140(12):3072-5. DOI:10.1093/brain/awx292.; Dos Passos G.R., Oliveira L.M., da Costa B.K. et al. MOG-IgG-asso-ciated optic neuritis, encephalitis, and myelitis: Lessons learned from neuromyelitis optica spectrum disorder. Front Neurol 2018;9:217. DOI:10.3389/fneur.2018.00217.; Fabriek B.O., Zwemmer J.N., Teunissen C.E. et al. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol 2005;161(1-2):190-4. DOI:10.1016/j.jneuroim.2004.12.018.; Jarius S., Paul F., Aktas O. et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018;15,134. DOI:10.1186/s12974-018-1144-2.; Jurynczyk M., Messina S., Woodhall M.R. et al. Clinical presentation and prognosis in MOG-antibody disease: A UK study. Brain 2017;140(12):3128-38. DOI:10.1093/brain/awx276.; Narayan R., Simpson A., Fritsche K. et al. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2018;25:66-72. DOI:10.1016/j.msard.2018.07.025.; Reindl M., Jarius S., Rostasy K., Berger T. Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they? Curr Opin Neurol 2017;30(3):295-301. DOI:10.1097/WCO.0000000000000446.; Reindl M., Schanda K., Woodhall M. et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 2020;7(2):e674. DOI:10.1212/NXI.0000000000000674.; Sato D.K., Callegaro D., Lana-Peixoto M.A. et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82(6):474-81. DOI:10.1212/WNL.0000000000000101.; Weber M.S., Derfuss T., Bruck W Anti-myelin oligodendrocyte glycoprotein antibody-associated central nervous system demyelination - a novel disease entity? JAMA Neurol 2018;75(8):909-10. DOI:10.1001/jamaneurol.2018.1055.; Weber M.S., Derfuss T., Metz I., Bruck W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord 2018;11:1756286418762083. DOI:10.1177/1756286418762083.; Weinshenker B.G., Wingerchuk D.M. Neuromyelitis spectrum disorders. Mayo Clin Proc 2017;92(4):663-79. DOI:10.1016/j.mayocp.2016.12.014.; Wingerchuk D.M., Banwell B., Bennett J.L. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177-89. DOI:10.1212/WNL.0000000000001729.; https://rjdn.abvpress.ru/jour/article/view/371